8:00h Transfer Only You Atocha Hotel – Hospital
8:30h
–
9:30h		 INDUSTRY SYMPOSIUM: Therakos. Mallinckrodt
Role of ECP Immunomodulation in current treatment strategies for CTCL
Moderator Prof Robert Knobler, Medical University of Vienna, Austria
08:30 – 08:55 ECP in the current International Guidelines & Clinical update
Prof Julia Scarisbrick, University Hospital Birmingham, United Kingdom
08:55 – 09:20 Role of ECP in the management of CTCL – Spanish experience
Prof Pablo Ortiz, Hospital Universitario 12 de Octubre, Madrid, Spain
09:20 – 09:30 Q&A
9:30h
Guest lecture 1
Prof. Miguel Angel Piris. Fundación Jiménez Díaz, Madrid
Cutaneous Lymphoma Diagnosis: tools and goals
Chair: PL Ortiz-Romero, J Scarisbrick

Miguel A Piris is pathologist, author of more than 470 articles in lymphoma diagnosis and cancer molecular pathogenesis, h-index: 78. He is currently Associate Chief of Pathology at the Fundacion Jimenez Diaz, Madrid, Spain.

Previous positions:
– Chief of Service at the Pathology Department in the Hospital Universitario Marques de Valdecilla, Santander, Spain and Scientific Director at the Research Institute IDIVAL. 2011-2017
– Director of the Molecular Pathology Program at the Spanish National Cancer Centre (CNIO) for 12 years , 1999-2011
– Past-president of the Spanish Society of Pathology and President of the European Association for Haematopathology 2004-2005.

Dr Piris has been the PI in multiple research projects funded by EU. MINECO-Spain and Spanish Association for Cancer Research
10:15h
Guest lecture 2:
Prof. Manuel Serrano. Institute for Reserach in Biomedicine (IRB), Barcelona.
Cellular senescence and its impotance in cancer therapy
Chair: PL Ortiz-Romero, J Scarisbrick

Manuel Serrano obtained his PhD in 1991, at the University of Madrid (UAM). From 1991 to 1996, Serrano worked as a postdoctoral researcher in the team of David Beach in Cold Spring Harbor Laboratory, NY. Since 1997, Manuel works in Spain, first in Madrid, at the National Center of Biotechnology (CNB) (until 2003) and at the Spanish National Cancer Research Center (CNIO). In 2017, Serrano moved to the Institute for Research in Biomedicine (IRB), in Barcelona.

Manuel Serrano is recognized in the fields of tumor suppression, senescence, aging and reprogramming. In 1993, he reported the discovery of the gene p16. This gene is among the most important anti-cancer genes but also a key inducer and marker of cellular senescence. Serrano pioneered the generation of genetically-modified mice resistant to cancer. Also, the Serrano laboratory demonstrated that cellular reprogramming into pluripotency is possible within tissues in vivo (Advance of the Year 2013, by Nature Medicine). The focus of his laboratory is to apply their knowledge on senescence and reprogramming to treat degenerative diseases and aging.
11:00h Coffee Break
11:30h
–
13:00h
Oral Presentations 05.
Clinical and Pre-clinical studies.
Chair: R Cowan, C Assaf , E Papadavid
11:30h Clin-O-01 Investigating clinical characteristics and outcomes of hypopigmented mycosis fungoides: retrospective review at a single tertiary referral center.
S Talluru
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA
11:42h Clin-O-02 Early versus Advanced stage folliculotropic micosis fungoides survival analysis in a reference latinamerican center.
HC Pérez Cely
National Institute of Cancer, Bogotá, Colombia
11:54h PreClin-O-01 Chimerized anti-ICOS 314.8 monoclonal antibodies inhibit tumor cells and regulatory T cells in patients with Sézary syndrome.
F Amatore
Centre de Recherche en Cancérologie de Marseille, INSERM U1068, CNRS, U7258, Aix Marseille Université, Institut Paoli-Calmettes, Marseille, France
12:06h PreClin-O-02 First xenograft and cell line of primary cutaneous diffuse large B-cell lymphoma, leg type.
JP Merlio
BRIC (Bordeaux Institute of Oncology) UMR1312, INSERM, Univ. Bordeaux and Dermatology Department, Bordeaux University Hospital, Bordeaux, France
12:18h PreClin-O-03 ICOSL: a new diagnostic marker and a new therapeutic target using an ICOS-Fc construct in Sézary syndrome?
J Giustiniani
INSERM U955, Henri-Mondor Hospital, Créteil, France
12:30h PreClin-O-04 Targeting CD70 in cutaneous T-cell lymphoma using an antibody-drug conjugate, SGN-CD70A, in patient-derived xenograft models.
WA Ai Zhuang
University of California, San Francisco, USA
12:42h PreClin-O-05 Evaluation of the role of different cell populations and immune regulators in Mycosis Fungoides microenvironment.
A Pavlidis
Department of Dermatology and Venereal Diseases, Attikon University General Hospital, National and Kapodistrian University of Athens, Greece
13:00h Lunch
13:30h
–
14:30h		 INDUSTRY SYMPOSIUM :  KYOWA KIRIN
How does targeted therapy affect immune dysfunction in mycosis fungoides and Sézary syndrome?
13:30h – 13:35h Welcome and introduction
Professor Pablo Ortiz-Romero
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
13:35h – 13:40 The tumour microenvironment in MF and SS
Professor Martine Bagot
Department of Dermatology and Inserm U976 chez Hôpital Saint Louis, Paris, France
13:40 – 13:55h Effect of mogamulizumab ▼ on the tumour microenvironment and anti-tumour immunity
Dr Hélène Moins-Teisserenc
Department of Hematology, Université de Paris, Institut de Recherche Saint-Louis, Paris, France
13:55 – 14:10h Presentation and mechanisms of mogamulizumab-associated rash
Professor Maxime Battistella
Department of Dermatopathology, Hopital Saint Louis, Paris, France
14:10 – 14:20h Case studies
Professor Martine Bagot and Professor Maxime Battistella
14:20 – 14:30h Q&A and close
POTELIGEO® (mogamulizumab) Prescribing Information can be found via the QR code:

▼ This medicine is subject to additional monitoring, which will expedite the detection of new safety information. Healthcare professionals are encouraged to report suspected adverse reactions.
This activity is developed and funded by Kyowa Kirin International PLC – All rights reserved.
KKI/INT/MOG/0636
Date of preparation: July 2022
14:30h
–
15:30h
Oral Presentations 6.
Preclinical Studies
Chairs: S Whittaker, J Nicolai, R Pujol
14:30h BioIns-O-16 Digital quantitative detection of DNA methylation biomarkers: A helpful tool in the early diagnosis of Sézary syndrome.
WH Zoutman
Department of Dermatology, Leiden University Medical Center (LUMC), Leiden, The Nederlands
14:42h BioIns-O-17 In vivo modelling of Cutaneous T-cell lymphoma: The role of SOCS1.
Y Luo
Department of Dermatology, Leiden University Medical Center (LUMC), Leiden, The Nederlands
14:54h BioIns-O-18 A 9-gene prognostic signature for predicting survival outcome in mycosis fungoides.
S Alberti-Violetti
Fondazione IRCCS Ca’Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy
15:06h BioIns-O-19 Molecular crosstalk between PLCΓ1 and STAT3 in Cutaneous T-Cell Lymphoma.
V Campbell
King’s College London, London, UK
15:18h BioIns-O-20 Transcriptomic landscape of primary cutaneous diffuse large B-cell lymphoma, leg type reveals novel therapeutic clues.
A Gros
CHU and University of Bordeaux, INSERM U1312, Bordeaux, France
15:30h Coffee Break
16:00h
–
17:00h
Oral Presentations 7.
Therapeutics
Chair E Hodak, P Quaglino, O Servitje
16:00h Ther-O-01 Lacutamab in patients with advanced mycosis fungoides according to KIR3DL2 expression: Stage 1 results from the TELLOMAK phase 2 trial.
M Bagot
Department of Dermatology, Saint-Louis Hospital, AP-HP, Paris University INSERM U976, Paris, France
16:12h Ther-O-02 The COBALT-LYM Study of CTX130: A Phase 1 Dose Escalation Study of CD70-Targeted Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients with Relapsed/Refractory (R/R) T-Cell Malignancies.
J Zain
Department of Hematology and Hematopoietic Cell Transpantation, City of Hope, Duarte, USA
16:24h Ther-O-03 Clinical Characteristics, Treatment Patterns, and Outcomes of Cytotoxic Cutaneous T-cell Lymphomas.
E Mou
University of Iowa, Iowa, USA
16:36h Ther-O-04 Dimethyl fumarate (DMF) therapy in CTCL – final results from a clinical phase II study.
JP Nicolay
Department of Dermatology, University Medical Center Mannheim, Mannheim, Germany
16:48h Ther-O-05 Clinical outcomes of single-agent chemotherapy in a diverse cohort of patients with recalcitrant cutaneous T-cell lymphoma.
D Weiner
Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA
17:00h
–
18:00h
Oral Presentations 8.
Therapeutics
Chair C Querfeld, A Cozzio, R Stadler
17:00h Ther-O-06 Near complete responses to concurrent brentuximab vedotin and ultra-hypofractionated low-dose total skin electron beam radiation in advanced CTCL.
M Oymanns
Helios Klinikum Krefeld, Academic Teaching Hospital of the University of Aachen, Krefeld, Germany
17:12h Ther-O-07 Combination Therapy With Chlormethine Gel and Narrow-Band Ultraviolet B for Patients With Mycosis Fungoides: A Case Series.
L Gleason
Department of Dermatology and Cutaneous Biology. Thomas Jefferson University, Philadelphia, USA
17:24h Ther-O-08 Broad-band ultraviolet A combined with narrow-band ultraviolet B: an effective modality for early folliculotropic mycosis fungoides and early mycosis fungoides refractory to narrow-band ultraviolet B.
I Amitay-Laish
Rabin Medical Center, Beilinson Hospital, Kyriat-Ono, Israel
17:36h Ther-O-09 New type of Mogamulizumab induced rash simulating Lupus miliaris disseminatus faciei.
C Mitteldorf
Department of Dermatology, Venereology and Allergology, University Medical Center, Göttingen, Germany
17:48h Ther-O-10 Real-world study of the use of pegylated interferon alfa for treatment of primary cutaneous T-cell lymphomas. An EORTC CLTF study.
K Mitsunaga
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
18:00h
–
19:00h
Oral Presentations 9.
Terapeutics
Chair R Knobler, L Geskins , R Fernández de Misa
18:00h Ther-O-11 Polatuzumab vedotin in combination with rituximab and bendamustine (Pola-RB) for relapsed primary cutaneous diffuse large B-cell lymphoma.
L Wilms
Helios Klinikum Krefeld, Academic Teaching Hospital of the University of Aachen, Krefeld, Germany
18:12h Ther-O-12 Time to next treatment and safety assessment in Cutaneous-T-cell lymphomas: a retrospective analysis on patients treated with bexarotene and acitretin.
G Roccuzzo
Dermatology Clinic, University of Turin, Turin, Italy
18:24h Ther-O-13 The effect of mogamulizumab on the malignant T cell population – A monocentric retrospective analysis.
JG Gosmann
University Clinic of Dermatology, Johanes Wesling Medical Centre, UKRUB, University of Bochum, Minden, Germany
18:36h Ther-O-14 A Post-hoc Analysis of Clinical Trial Data Shows That Prior Phototherapy Does Not Affect Response to Chlormethine Gel in Patients With Mycosis Fungoides.
C Assaf
Department of Dermatology, Helios Klinikum Krefeld, Germany
18:48h Ther-O-15 TUB-010, a novel antibody drug conjugate with reduced nonspecific toxicity profile based on Tub-tag technology widens the therapeutic window of targeting CD30.
M Gerlach
Tubulis GmbH, Planegg, Germany
19:00h EORTC CLTG General Assembly

Profesors Julia Scarisbrick, Emmanuella Guenova and Evangelia Papadavid
19:30h ISCL Assembly

Chairpersons: Emmila Hodak, Julia Scarisbrick, Larisa Geskin
19:45h Poster session 2. Poster walk
Clin-PO-06 A case series of three male patients with blastic plasmocytoid dendritic
cell neoplasm
A Osmancevic
Department of Dermatology, Sahlgrenska University Hospital, Gothenburg, Sweden
Clin-PO-11 Estimates of the rate of growth of lymph nodes measured volumetrically
predicts survival in cutaneous T-cell lymphoma (CTCL)
LM Fahmy
Cutaneous Oncology Research Fellow, Columbia University, New York, USA
Ther-PO-22 Intralesional brentuximab vedotin: our experience in the treatment of
CD30+ primary cutaneous T-cell lymphomas
JA Arroyo Andrés
Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain
20:00h Transfer Hospital – Hotel Only You Atocha
21:00h CONGRESS DINNER

Nubel Restaurant (The Museo Reina Sofia) – Nubel Building
Ronda de Atocha Street, Num 2 (entrance by Patio Nubel)
(10 minutes walking distance)
23:30h Visit The Museo Reina Sofia

We will have a Visit after the Congress Dinner